Zetia Pay-For-Delay MDL Should Press On, Magistrate Says

Law360 (February 7, 2019, 7:52 PM EST) -- Zetia buyers have sufficiently alleged that Merck & Co. Inc. and Glenmark Pharmaceuticals Inc. kept a generic of the cholesterol medication off the market using a so-called pay-for-delay agreement, a Virginia federal magistrate judge has said.

U.S. Magistrate Judge Douglas E. Miller asked the court Wednesday to trim one per se Sherman Act claim and some state claims from the multidistrict litigation. Otherwise, he said in his report and recommendation that Merck and Glenmark's motions to dismiss should be rejected, leaving the central antitrust questions on the table.

The potential classes of direct purchasers, end-payors and retailers claim the drugmakers violated...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!